by Anastasiia Rohozianska
Clinical development is still shaped by a stubborn asymmetry: only around one in ten drug candidates that enter human testing ever reaches approval, and Phase II/III failures remain the biggest …
Read More
by Andrii Buvailo, PhD
A specific idea is increasingly taking hold in 2026: that the raw material for the next generation of medicines is not more compute or cleverer algorithms, but stored human biology …
Read More
by Andrii Buvailo, PhD
Isomorphic Labs is in talks to raise about $5 billion at a valuation of about $50 billion, Bloomberg reported on November 4. The company has already raised about $2.7 billion from outside …
Read More
by Andrii Buvailo, PhD
In October, Biohub, the Chan Zuckerberg science organization, expanded its Virtual Biology Initiative to $1.8 billion. The money pays for open, standardized data to train virtual cells: AI models that …
Read More
by BiopharmaTrend , Roman Kasianov, Anastasiia Rohozianska, Andrii Buvailo, PhD
Latest changes · October 30, 2026 Biohub’s data push hit $1.8B with DOE, NIH, Google DeepMind, Isomorphic and Meta joining; commercial funders get a one-year head start on the data. One …
Read More
by Andrii Buvailo, PhD
Anthropic filed for its IPO with the SEC on Monday, and its S-1 shows that 9 of the 10 largest pharmaceutical companies in the Fortune 500 each spent at least …
Read More
